PEPSYN Biotech invites you to visit us at Booth 3W06, API China 2026 in Shanghai from May 13-15. Explore our premium peptide API catalog and custom synthesis services. Contact us to schedule an on-site meeting.

本文针对三种名称相近的铜肽类原料，从化学特性、核心结构、功效定位及应用场景进行专业解析，明确三者本质区别；同时结合业务实操，重点说明原料一（CAS 49557-75-7）作为注射原料的安全风险，为原料采购、配方研发、客户对接及合规管控提供科学参考，适配海外业务需求。​

The metabolic therapeutic landscape is shifting from simple peptide analogs to Unimolecular Polypharmacy. While GLP-1 mono-agonists (e.g., Semaglutide) have revolutionized obesity care, the recent 19.7% weight reduction observed in the China Phase II trial of UBT251 represents a quantum leap. This triple agonist doesn't just iterate; it redefines the pharmacological ceiling for non-surgical weight loss.